These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37892756)

  • 1. RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia.
    Seccia TM; Shagjaa T; Morpurgo M; Caroccia B; Sanga V; Faoro S; Venturini F; Iadicicco G; Lococo S; Mazzitelli M; Farnia F; Fioretto P; Kobayashi Y; Gregori D; Rossi GP
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
    Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
    Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
    Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA
    Clin Pharmacokinet; 2022 Oct; 61(10):1331-1343. PubMed ID: 36040613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis.
    Wei M; Li T; Liu S; Wang Y; Tran C; Ao G
    Jpn J Infect Dis; 2024 May; 77(3):182-186. PubMed ID: 38296543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
    Takahashi W; Yoneda T; Koba H; Ueda T; Tsuji N; Ogawa H; Asakura H
    Int J Infect Dis; 2021 Jan; 102():529-531. PubMed ID: 33157292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.
    Zhuravel SV; Khmelnitskiy OK; Burlaka OO; Gritsan AI; Goloshchekin BM; Kim S; Hong KY
    EClinicalMedicine; 2021 Nov; 41():101169. PubMed ID: 34723164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
    Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial of Nafamostat for Covid-19.
    Morpeth SC; Venkatesh B; Totterdell JA; McPhee GM; Mahar RK; Jones M; Bandara M; Barina LA; Basnet BK; Bowen AC; Burke AJ; Cochrane B; Denholm JT; Dhungana A; Dore GJ; Dotel R; Duffy E; Dummer J; Foo H; Gilbey TL; Hammond NE; Hudson BJ; Jha V; Jevaji PR; John O; Joshi R; Kang G; Kaur B; Kim S; Das SK; Lau JSY; Littleford R; Marsh JA; Marschner IC; Matthews G; Maze MJ; McArthur CJ; McFadyen JD; McMahon JH; McQuilten ZK; Molton J; Mora JM; Mudaliar V; Nguyen V; O'Sullivan MVN; Pant S; Park JE; Paterson DL; Price DJ; Raymond N; Rees MA; Robinson JO; Rogers BA; Ryu WS; Sasadeusz J; Shum O; Snelling TL; Sommerville C; Trask N; Lewin SR; Hills TE; Davis JS; Roberts JA; Tong SYC
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300132. PubMed ID: 38320527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
    Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Salleh MZ; Deris ZZ
    Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study.
    Soma T; Fujii K; Yoshifuji A; Maruki T; Itoh K; Taniyama D; Kikuchi T; Hasegawa N; Nakamura M
    Jpn J Infect Dis; 2022 Sep; 75(5):484-489. PubMed ID: 35491224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.